- Conbercept: Another Anti-VEGF Agent for Wet-AMD Treatment
- Mar 4, 2014 Clinical Updates
- Regeneron and Bayer Seek Eylea Marketing Authorization for DME Treatment in Japan
- Mar 4, 2014 Industry News
- Home Monitoring System Shows Promise for Preserving Visual Acuity in Wet-AMD Patients
- Feb 26, 2014 Clinical Updates
- Study Finds ICD-10 Implementation Costs 'Much More Disruptive'
- Feb 12, 2014 Advocacy & Practice Updates
- Two-Year Results of Phase 3 VISTA Trial of Aflibercept for DME Treatment Show Sustained Vision Improvement
- Feb 12, 2014 Industry News
- Comparing Wet-AMD Patients’ Real-World Use of Ranibizumab and Aflibercept
- Feb 10, 2014 Clinical Updates
2013 Winter Issue, Vol. 31, No. 5, Iss. 52
In this issue:
From the Editor's Desk
Like Hell It's Minimally Invasive! Let's Not Trivialize What We Do
Clinical Trials: Future Pathways
Emixustat Hydrochloride: New Hope for Atrophic AMD?
Global Trends in Retina Symposium Explores Practice Patterns Worldwide
Should Partnership Agreements Include a Mandatory Retirement Age?